SS-31 (Elamipretide): What It Is Studied Alongside
SS-31 (elamipretide) is a mitochondria-targeted tetrapeptide studied in models of radiation injury, synucleinopathy, Friedreich ataxia, and metabolic liver disease. This page summarises the research context and the compo
SS-31, also known as elamipretide, is a synthetic mitochondria-targeted tetrapeptide. It is classified as a cell-permeable aromatic-cationic peptide, and its sequence comprises alternating cationic and aromatic residues. The evidence block does not provide the full sequence, molecular formula, or molecular weight. The work described here centres on the mitochondrial inner membrane and its interaction with cardiolipin, a phospholipid that is critical for cristae structure and respiratory chain function.
In the studies cited below, SS-31 is examined alongside a range of experimental models and comparator compounds. These include ionizing radiation in cardiomyocytes, α-synuclein oligomers in neuronal models, clinical assessment in Friedreich ataxia, and nutritional stress in aged female mice. The sections that follow describe each context in turn, with explicit notes where the evidence is animal-only or in vitro.
Research Studies
SS-31 and radiation-induced cardiomyocyte senescence
Exposure to ionizing radiation, whether from radiotherapy or accidental sources, can damage the heart. One manifestation is cardiomyocyte senescence, for which no preventive strategies are currently available. A study evaluated the effects of the mitochondrial-targeted peptide SS-31 (elamipretide) on radiation-induced senescence in cardiomyoblast H9C2 cells and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) [1].
In that work, γ-radiation at doses of 2, 5, and 10 Gy inhibited H9C2 proliferation in a dose-dependent manner and induced senescence-associated beta-galactosidase (SA-β-gal) staining, a marker of cellular senescence. The study reported that SS-31 attenuated these effects. This finding is in vitro only; no animal or human data on radiation-induced cardiac senescence are provided in the evidence block.
SS-31 and α-synuclein membrane binding and aggregation
α-Synuclein aggregation and its interaction with lipid membranes are closely associated with Parkinson's disease and a class of related syndromes termed synucleinopathies. A study explored whether SS-31 could modulate α-synuclein's interaction with lipid membranes and mitigate mitochondrial impairment induced by α-synuclein oligomers [2].
Using fluorescence correlation spectroscopy and fluorescence anisotropy, the investigators demonstrated that SS-31 displaces both wild-type and N-terminal acetylated α-synuclein from membranes. The work also reported restoration of impaired mitochondrial function in the presence of α-synuclein oligomers. These experiments were conducted in cell-free and cell-based systems; the evidence block does not indicate whether animal models of synucleinopathy were used.
SS-31 and Friedreich ataxia vision loss
An investigator-initiated study is evaluating elamipretide in Friedreich ataxia (FRDA), with the primary aim of assessing safety, tolerability, and activity in treating vision loss associated with the condition [3]. This is a clinical trial; the evidence block does not provide results, participant numbers, or dosing information. It is listed here to indicate the clinical context in which the compound is being studied.
SS-31 and metabolic dysfunction-associated steatotic liver disease (MASLD) in aged female mice
A comparative study examined mitochondria-targeted compounds in aged female mice under nutritional stress, focusing on metabolic dysfunction-associated steatotic liver disease (MASLD) [4]. MASLD is a major cause of cirrhosis, liver cancer, and cardiovascular disease, and early mitochondrial dysfunction is thought to drive lipid imbalance, inflammation, and fibrosis. The study compared MitoQ and SS-31 (elamipretide) in this model. This is an animal-only study; the evidence block does not provide quantitative outcomes or effect sizes.
SS-31 and peptide therapies for musculoskeletal injuries
A review of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance discusses peptides as a pharmacological class between small-molecule drugs and large proteins [5]. The review notes that peptide use in sports medicine is expanding, driven by patient demand for accelerated injury recovery and performance enhancement. SS-31 is mentioned within this broader context; the evidence block does not specify any findings unique to SS-31 in musculoskeletal models.
SS-31 and mitochondrial membrane interactions
The defining property of SS-31 is its ability to bind the mitochondrial inner membrane, particularly cardiolipin. This interaction is central to its studied mechanisms. In the α-synuclein work, SS-31's membrane displacement activity was directly measured [2]. In the radiation study, the mitochondrial-targeted nature of the peptide was the rationale for testing it against radiation-induced senescence [1]. No other membrane-interaction studies are provided in the evidence block.
SS-31 and oxidative stress reduction
SS-31 is described as having known properties of mitochondrial inner membrane binding and oxidative stress reduction [2]. The evidence block does not provide a dedicated study on oxidative stress markers alone; this property is referenced as background in the α-synuclein investigation. No quantitative measures of reactive oxygen species or antioxidant capacity are given.
SS-31 and comparative mitochondria-targeted agents
In the MASLD study, SS-31 was compared directly with MitoQ, another mitochondria-targeted compound [4]. The comparison was conducted in aged female mice under nutritional stress. The evidence block does not report which agent performed better or on which endpoints. This is the only head-to-head comparison involving SS-31 in the provided evidence.
SS-31 and clinical safety assessment
The Friedreich ataxia trial is designed to evaluate safety and tolerability alongside activity [3]. This is the only clinical study in the evidence block. No safety data, adverse event rates, or tolerability outcomes are provided. The trial is listed as an investigator-initiated study, and its results are not yet available in the evidence block.
Summary of evidence contexts
| Context | Model or population | Key finding reported | Evidence type |
|---|---|---|---|
| Radiation-induced senescence | H9C2 cells and hiPSC-CMs | SS-31 attenuated SA-β-gal staining and proliferation inhibition | In vitro |
| α-Synuclein aggregation | Cell-free and cell-based systems | SS-31 displaced α-synuclein from membranes and restored mitochondrial function | In vitro |
| Friedreich ataxia vision loss | Clinical trial participants | Safety, tolerability, and activity being evaluated | Clinical trial (no results) |
| MASLD | Aged female mice under nutritional stress | Comparative evaluation with MitoQ | Animal-only |
| Musculoskeletal injuries | Review of peptide therapies | SS-31 mentioned in broader peptide context | Review |
If you are reading this for personal health reasons
This material is sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.
Sources
- [1] Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence
- [2] Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function
- [3] FRDA Investigator Initiated Study (IIS) With Elamipretide
- [4] Targeting Mitochondria in MASLD: Comparative Evaluation of MitoQ and SS-31 (Elamipretide) in Aged Female Mice under Nutritional Stress
- [5] Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance